Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

Study of High Efficient Killing Cell Therapy for Advanced NSCLC — Stella

Home/Non Small Cell Lung Cancer/Study of High Efficient Killing Cell Therapy for Advanced NSCLC

View on ClinicalTrials.gov

Recruiting

Back to Non Small Cell Lung Cancer trials

Study of High Efficient Killing Cell Therapy for Advanced NSCLC

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

China

Ruijin Hospital, Shanghai

Key details

Phase

Early testing

Sponsor

Ruijin Hospital

Collaborators

Shanghai Houchao Biotechnology Co., Ltd

Enrollment target

~15 participants

Started

September 2017

Primary completion

May 2025

This trial's estimated completion date has passed — the record may not be fully up to date.

Age range

18 Years – 70 Years

Last updated November 2024

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.